Peter Attia· MD
there's this genomic test we get to help us decide whether chemotherapy is going to be valuable and with that about 2third of the women who were previously offered chemotherapy can now avoid chemotherapy
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
there's this genomic test we get to help us decide whether chemotherapy is going to be valuable and with that about 2third of the women who were previously offered chemotherapy can now avoid chemotherapy
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
there's this genomic test we get to help us decide whether chemotherapy is going to be valuable and with that about 2third of the women women who were previously offered chemotherapy can now avoid chemotherapy
those have been shown to be very powerful at figuring out who does and more importantly who does not need chemotherapy
Large randomized controlled trial finds that 70% of women with early-stage invasive breast cancer do not need chemotherapy in addition to hormone therapy based on a genomic test for this type of breast cancer.